cnbc exclusive: eisai u.s. ceo on alzheimer's drug approval
Published 1 year ago • 2.4K plays • Length 5:57Download video MP4
Download video MP3
Similar videos
-
3:54
eisai ceo on alzheimer's treatment drug trial results
-
4:06
many health systems are already ready for 'leqembi' roll out, says eisai ceo ivan cheung
-
3:52
we believe the risk-benefit profile for our alzheimer's drug is acceptable, says eisai u.s. ceo
-
3:58
eisai's alzheimer's drug reduces cognitive decline by 27% in trial patients
-
1:31
alzheimer's drug decision day: fda to decide on biogen and eisai treatments
-
2:57
florida dems say they’re overwhelmed with volunteer offers following vp harris bid
-
5:33
renewable energy will grow regardless of election outcome, says aes ceo andrés gluski
-
14:23
is toyota late to evs?
-
2:54
biogen and eisai to reveal results of alzheimer's drug trial
-
1:07
biogen and eisai report successful test on alzheimer's treatment
-
3:49
biogen ceo on fda approval for its alzheimer's drug
-
1:21
biogen shares drop despite positive alzheimer's drug results
-
5:19
analyst: it's unclear whether biogen's new alzheimer's drug will get approved
-
3:46
jefferies' michael yee on biogen as fda could be on the verge of approving alzheimer's drug
-
1:50
jim cramer: there will be push back on biogen's alzheimer's drug price
-
4:37
biogen alzheimer's drug could get medicare coverage in 2025 if approved, says dr. scott gottlieb
-
1:07
fda approves biogen's alzheimer's drug
-
2:23
biogen to seek fda approval for alzheimer's drug aducanumab
-
4:30
eli lilly ceo on fda approval pathway for alzheimer's drugs
-
1:48
biogen reopens following fda approval of company's alzheimer drug
-
1:53
fda approves biogen alzheimer's drug, first new therapy for the disease in nearly two decades
-
7:37
sell-off in big tech is a 'psychological rotation', says neuberger berman's steve eisman